Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib with R-GEMOX-Dexa in R/R Non-GCB DLBCL
NCT02692248Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Apr 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by GELTAMO. Started Apr 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02692248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692248.